Growth Hormone Secretagogue Research Peptides Guide

This guide covers 12 research peptides in the Growth Hormone Secretagogue category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.

Ipamorelin is recognized as the most selective growth hormone secretagogue available, characterized as a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5). Its primary mechanism involves stimulating the pituitary gland to release growth hormone (GH) in a pulsatile manner, while notably sparing the secretion of cortisol, prolactin, and appetite modulation. This selectivity may confer a favorable safety profile compared to other GHS. Research suggests potential applications in anti-aging, body composition enhancement, and sleep improvement. However, the current evidence base is limited to preclinical studies, and Ipamorelin remains classified as a research-only compound, not approved for human use.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), initially developed by ConjuChem Technologies to address HIV-associated lipodystrophy. It exists in two formulations: one with Drug Affinity Complex (DAC), which extends its half-life to approximately 5.8-8.1 days, and another without DAC (Mod GRF 1-29), which allows for a shorter, more physiological release pattern with a half-life of around 30 minutes. A series of randomized, placebo-controlled trials conducted in 2006 (Teichman et al.) demonstrated dose-dependent increases in GH (2-10 fold) and IGF-1 (1.5-3 fold) in healthy adults aged 21-61. While the DAC version offers prolonged effects, the non-DAC variant is often considered safer due to its closer mimicry of natural GH pulsatility. Despite these findings, CJC-1295 is still categorized as research-only and is not approved for clinical use.

Sermorelin is a synthetic peptide consisting of 29 amino acids (MW ~3357.9 g/mol) that mirrors the initial segment of natural growth hormone-releasing hormone (GHRH). It functions by preserving the body's intrinsic GH feedback mechanisms, particularly through somatostatin, which may render it a safer alternative to exogenous human growth hormone (HGH). The most significant evidence for its efficacy stems from a 1997 trial published in the Journal of Clinical Endocrinology & Metabolism (JCEM), which reported improvements in IGF-1 levels, body composition, and overall well-being over a 5-month period. Despite its previous FDA approval under the brand name Geref, it is now primarily used off-label through compounding, indicating a shift in its clinical availability and application.

Tesamorelin is a synthetic peptide approved by the FDA for the treatment of HIV-associated lipodystrophy, marketed under the brand name Egrifta. It promotes the endogenous production of growth hormone and insulin-like growth factor 1 (IGF-1). Phase 3 clinical trials demonstrated significant reductions in visceral fat after 26 weeks of treatment, which were accompanied by a generally well-tolerated safety profile. The approval of Tesamorelin underscores its therapeutic potential in specific populations, particularly those experiencing body composition changes related to HIV. The ongoing evaluation of its long-term effects and safety continues to be an area of interest in clinical research.

GHRP-6, or Growth Hormone-Releasing Peptide 6, is a synthetic hexapeptide that acts as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a). Its mechanism results in the stimulation of pulsatile GH release from the pituitary gland while maintaining physiological feedback controls. Notably, GHRP-6 is recognized for its strong appetite-stimulating effects due to its interaction with the ghrelin receptor. In addition to its endocrine functions, preclinical studies have suggested that GHRP-6 may possess cytoprotective properties through the CD36 receptor, indicating potential cardioprotective, neuroprotective, and anti-fibrotic effects. However, as GHRP-6 is still classified as research-only, its application in human subjects remains unsupported by regulatory approval.

GHRP-2, known chemically as pralmorelin, is a synthetic hexapeptide that acts as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R). Studies indicate that GHRP-2 induces a robust, dose-dependent release of growth hormone (GH), demonstrating a higher potency compared to GHRP-6 while exhibiting less appetite stimulation. In clinical settings, particularly in Japan, it has been approved as a diagnostic agent for growth hormone deficiency, showing sustained efficacy in enhancing growth velocity in GH-deficient pediatric populations over 8 to 24 months. Safety profiles observed in clinical trials suggest that GHRP-2 maintains a placebo-like safety profile when administered at therapeutic doses, although further research is necessary to explore its long-term effects and potential applications beyond diagnosis. The primary use case for GHRP-2 remains centered on body composition management.

MK-677, also known as Ibutamoren, is a non-peptide ghrelin receptor agonist that offers a unique advantage over traditional injectable growth hormone peptides by being orally active. Research indicates that MK-677 stimulates GH release and sustains elevated levels of GH and IGF-1 for up to 24 hours, making it a compelling option for various therapeutic applications. Multiple Phase II clinical trials have been conducted to assess its efficacy in diverse areas, including anti-aging, body composition enhancement, and sleep quality improvement. While promising results have emerged, MK-677 remains investigational and has not received FDA approval, necessitating further studies to confirm its safety and effectiveness in long-term use. The compound's potential for improving body composition and its effects on sleep patterns are of particular interest within the research community.

Hexarelin is a synthetic hexapeptide recognized for its strong growth hormone secretagogue activity, primarily through its binding to the ghrelin receptor (GHS-R1a). Research suggests that Hexarelin is one of the most potent GHRPs, capable of inducing a greater GH release compared to GHRH alone. However, a significant limitation is its tendency for rapid receptor desensitization, which may restrict its use to short cycles of 4-8 weeks. Despite this drawback, Hexarelin has garnered interest due to its cardioprotective properties that appear to function independently of GH release. This dual action may offer potential therapeutic avenues, particularly in the context of body composition and anti-aging strategies. Phase II clinical trials have been completed, but development has been discontinued, primarily due to concerns about tolerance and desensitization.

Alexamorelin is a synthetic growth hormone-releasing peptide that shares structural similarities with GHRP-6. While it has been explored in limited preclinical studies, the compound has not progressed to clinical trials, resulting in a scarcity of published data. The lack of clinical development has rendered Alexamorelin an obscure research compound, primarily utilized in basic research settings focused on growth hormone modulation. Its potential applications remain largely theoretical, with no established use cases or approved indications, highlighting the necessity for further investigation to elucidate its pharmacological profile and therapeutic value.

Tabimorelin, also referred to as NN703, is a synthetic growth hormone secretagogue developed by Novo Nordisk. It completed Phase II clinical trials, demonstrating significant GH release in both healthy individuals and those with GH deficiency. Despite its promising pharmacological activity, development was ultimately discontinued, likely due to an insufficient efficacy-to-side-effect ratio for chronic use. Tabimorelin remains one of the better-characterized oral GH secretagogues in the literature, providing a foundation for future research into oral administration of growth hormone modulators. Its primary use case is situated within the realm of growth hormone research, as the exploration of oral GHS continues to be a topic of interest in the field.

Macimorelin, marketed as Macrilen, is an orally active growth hormone secretagogue that received FDA approval in December 2017 for the diagnosis of adult growth hormone deficiency (AGHD). The mechanism of action involves stimulating GH release, with the resulting peak GH response serving as a diagnostic indicator. Clinical trials have demonstrated a 92% concordance rate with the insulin tolerance test (ITT), which was previously regarded as the gold standard for diagnosing AGHD. Developed by Aeterna Zentaris, Macimorelin's approval marks a significant advancement in diagnostic options for GH deficiency. The compound's established efficacy in clinical settings underscores its importance in endocrine diagnostics, although its application is limited to diagnostic purposes rather than therapeutic treatment.

Anamorelin is a synthetic ghrelin receptor (GHS-R1a) agonist specifically designed to address cancer-related cachexia, a debilitating condition characterized by significant weight loss and muscle wasting in cancer patients. Unlike endogenous ghrelin, which has a very short half-life, anamorelin offers a pharmacokinetic profile that supports once-daily oral dosing, allowing for sustained receptor activation throughout the day. In 2021, anamorelin received regulatory approval in Japan for the treatment of cachexia associated with non-small cell lung cancer (NSCLC), gastric, pancreatic, and colorectal cancers. This approval marks a significant milestone, as it is one of the few peptide-derived therapeutics specifically indicated for cachexia. The approval was based on results from the ROMANA 1 and 2 Phase III trials, which demonstrated its efficacy in improving appetite and preserving lean body mass in cancer patients. However, it is important to note that anamorelin has not received approval from the FDA or EMA, indicating that further research may be needed to establish its safety and efficacy in broader populations.